<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36386945</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-861X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in nutrition</Title><ISOAbbreviation>Front Nutr</ISOAbbreviation></Journal><ArticleTitle>The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID.</ArticleTitle><Pagination><StartPage>1034169</StartPage><MedlinePgn>1034169</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1034169</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fnut.2022.1034169</ELocationID><Abstract><AbstractText>Long-COVID is a syndrome characterized by debilitating symptoms that persist over 3 months after infection with the SARS-CoV-2 virus. It affects 15 to 33% of COVID-19 recovered patients and has no dedicated treatment. First, we found that &#x3b2;-caryophyllene and pregnenolone have a significant synergistic effect in the resolution of LPS-induced sepsis and inflammation in mice. Then we combined these two compounds with seven others and designed a unique dietary supplement formulation to alleviate long COVID inflammatory and neurological disorders. We performed a one-arm open-labeled study at a single site with 51 eligible patients from 18 states. Each participant recorded the severity level of 12 symptoms (including fatigue, weakness, cardiac and neurological symptoms, shortness of breath, gastrointestinal disorders, ageusia or anosmia, anxiety, joint pain, rash, cough, and insomnia) at baseline, 2- and 4-week time points. On average, all the symptoms were significantly milder after 2 weeks, with further improvement after 4 weeks. Importantly, each symptom was significantly attenuated in 72 to 84% of the participants. There were no significant adverse effects. Our data indicate that the use of this nutraceutical product is a safe and significantly efficient option to reduce multiple symptoms of long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Gaylis, Kreychman, Sagliani, Mograbi and Gabet.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gaylis</LastName><ForeName>Norman B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>The COVID Long Haul Center at Arthritis &amp; Rheumatic Disease Specialties (AARDS), Miami, FL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreychman</LastName><ForeName>Ida</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagliani</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The COVID Long Haul Center at Arthritis &amp; Rheumatic Disease Specialties (AARDS), Miami, FL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mograbi</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Independent Researcher, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabet</LastName><ForeName>Yankel</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Nutr</MedlineTA><NlmUniqueID>101642264</NlmUniqueID><ISSNLinking>2296-861X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CB2 agonists</Keyword><Keyword MajorTopicYN="N">cannabinoids</Keyword><Keyword MajorTopicYN="N">dietary (food) supplements</Keyword><Keyword MajorTopicYN="N">immunology and inflammation</Keyword><Keyword MajorTopicYN="N">long-COVID-19</Keyword></KeywordList><CoiStatement>The clinical study has been sponsored in part by NTN Enterprises LLC. Authors NG and JM own stock in NTN Enterprises LLC. Ramot, the technology transfer company of Tel Aviv University also owns stock in this company, and YG was an employee of Tel Aviv University. Authors JM and YG are the inventors of patent PCT/IL2022/050676, which exclusive rights has been acquired by NTN Enterprises LLC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>17</Day><Hour>11</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36386945</ArticleId><ArticleId IdType="pmc">PMC9641293</ArticleId><ArticleId IdType="doi">10.3389/fnut.2022.1034169</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. (2020) 26:1017&#x2013;32. 10.1038/s41591-020-0968-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0968-3</ArticleId><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. (2021) 18:e1003773. 10.1371/journal.pmed.1003773</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. (2022) 400:452&#x2013;61. 10.1016/S0140-6736(22)01214-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM. The Costs of Long COVID. JAMA Health Forum. (2022) 3:e221809. 10.1001/jamahealthforum.2022.1809</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2022.1809</ArticleId><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re&#x2019;em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. (2021) 38:101019. 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Noval Rivas M, Porritt RA, Cheng MH, Bahar I, Arditi M. Multisystem inflammatory syndrome in children and long COVID: the SARS-CoV-2 viral superantigen hypothesis. Front Immunol. (2022) 13:941009. 10.3389/fimmu.2022.941009</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.941009</ArticleId><ArticleId IdType="pmc">PMC9300823</ArticleId><ArticleId IdType="pubmed">35874696</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Shima S, Mizutani Y, Ueda A, Ito M. [Long COVID: pathogenesis and therapeutic approach]. Brain Nerve. (2022) 74:879&#x2013;84. 10.11477/mf.1416202142</Citation><ArticleIdList><ArticleId IdType="doi">10.11477/mf.1416202142</ArticleId><ArticleId IdType="pubmed">35860935</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantzer R, O&#x2019;Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. (2008) 9:46&#x2013;56. 10.1038/nrn2297</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2297</ArticleId><ArticleId IdType="pmc">PMC2919277</ArticleId><ArticleId IdType="pubmed">18073775</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu LD, Duricka DL. Stellate ganglion block reduces symptoms of long COVID: a case series. J Neuroimmunol. (2022) 362:577784. 10.1016/j.jneuroim.2021.577784</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577784</ArticleId><ArticleId IdType="pmc">PMC8653406</ArticleId><ArticleId IdType="pubmed">34922127</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. (2020) 370:m3026. 10.1136/bmj.m3026</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. (2021) 114:428&#x2013;42. 10.1177/01410768211032850</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C. COVID-19 long haulers. Nat Biotechnol. (2021) 39:908&#x2013;13. 10.1038/s41587-021-00984-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-00984-7</ArticleId><ArticleId IdType="pmc">PMC8277229</ArticleId><ArticleId IdType="pubmed">34257426</ArticleId></ArticleIdList></Reference><Reference><Citation>Siso-Almirall A, Brito-Zeron P, Conangla Ferrin L, Kostov B, Moragas Moreno A, Mestres J, et al. Long Covid-19: proposed primary care clinical guidelines for diagnosis and disease management. Int J Environ Res Public Health. (2021) 18:4350. 10.3390/ijerph18084350</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18084350</ArticleId><ArticleId IdType="pmc">PMC8073248</ArticleId><ArticleId IdType="pubmed">33923972</ArticleId></ArticleIdList></Reference><Reference><Citation>Chippa V, Aleem A, Anjum F. Post Acute Coronavirus (COVID-19) Syndrome. Treasure Island, FL: StatPearls; (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34033370</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagoor Meeran MF, Sharma C, Goyal SN, Kumar S, Ojha S. CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections. Drug Dev Res. (2021) 82:7&#x2013;11. 10.1002/ddr.21752</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.21752</ArticleId><ArticleId IdType="pmc">PMC7753678</ArticleId><ArticleId IdType="pubmed">33190277</ArticleId></ArticleIdList></Reference><Reference><Citation>Raphael-Mizrahi B, Attar-Namdar M, Chourasia M, Cascio MG, Shurki A, Tam J, et al. Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2. Elife. (2022) 11:e65834. 10.7554/eLife.65834</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.65834</ArticleId><ArticleId IdType="pmc">PMC9154745</ArticleId><ArticleId IdType="pubmed">35604006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ, et al. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U.S.A. (2008) 105:9099&#x2013;104. 10.1073/pnas.0803601105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0803601105</ArticleId><ArticleId IdType="pmc">PMC2449371</ArticleId><ArticleId IdType="pubmed">18574142</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Kaabi JA, et al. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. (2021) 140:111639. 10.1016/j.biopha.2021.111639</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.111639</ArticleId><ArticleId IdType="pubmed">34091179</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson E, Weinberg M, Wright WA. Pregnenolone. J Clin Endocrinol Metab. (1950) 10:455&#x2013;74. 10.1210/jcem-10-4-455</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem-10-4-455</ArticleId><ArticleId IdType="pubmed">15415436</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold R, Schmied M, Tontsch U, Hartung HP, Wekerle H, Toyka KV, et al. Antigen presentation by astrocytes primes rat T lymphocytes for apoptotic cell death. A model for T-cell apoptosis in vivo. Brain. (1996) 119 (Pt 2):651&#x2013;9. 10.1093/brain/119.2.651</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/119.2.651</ArticleId><ArticleId IdType="pubmed">8800954</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacchio MS, Ashwell JD, King LB. A positive role for thymus-derived steroids in formation of the T-cell repertoire. Ann N Y Acad Sci. (1998) 840:317&#x2013;27. 10.1111/j.1749-6632.1998.tb09571.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1998.tb09571.x</ArticleId><ArticleId IdType="pubmed">9629259</ArticleId></ArticleIdList></Reference><Reference><Citation>Murugan S, Jakka P, Namani S, Mujumdar V, Radhakrishnan G. The neurosteroid pregnenolone promotes degradation of key proteins in the innate immune signaling to suppress inflammation. J Biol Chem. (2019) 294:4596&#x2013;607. 10.1074/jbc.RA118.005543</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.005543</ArticleId><ArticleId IdType="pmc">PMC6433066</ArticleId><ArticleId IdType="pubmed">30647133</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Zhang C, Guo H, Chen J, Tao Y, Wang F, et al. Pregnenolone inhibits osteoclast differentiation and protects against lipopolysaccharide-induced inflammatory bone destruction and ovariectomy-induced bone loss. Front Pharmacol. (2020) 11:360. 10.3389/fphar.2020.00360</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00360</ArticleId><ArticleId IdType="pmc">PMC7135856</ArticleId><ArticleId IdType="pubmed">32292342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragozzino FJ, Arnold RA, Fenwick AJ, Riley TP, Lindberg JEM, Peterson B, et al. TRPM3 expression and control of glutamate release from primary vagal afferent neurons. J Neurophysiol. (2021) 125:199&#x2013;210. 10.1152/jn.00229.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00229.2020</ArticleId><ArticleId IdType="pmc">PMC8087376</ArticleId><ArticleId IdType="pubmed">33296617</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrabi SS, Kaushik P, Mumtaz SM, Alam MM, Tabassum H, Parvez S. Pregnenolone attenuates the ischemia-induced neurological deficit in the transient middle cerebral artery occlusion model of rats. ACS Omega. (2022) 7:19122&#x2013;30. 10.1021/acsomega.1c07016</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.1c07016</ArticleId><ArticleId IdType="pmc">PMC9202047</ArticleId><ArticleId IdType="pubmed">35721911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez S, Haddad-Tovolli R, Radosevic M, Toledo M, Pane A, Alcolea D, et al. Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders. Cell Metab. (2022) 34:269&#x2013;284.e9. 10.1016/j.cmet.2021.12.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.12.023</ArticleId><ArticleId IdType="pmc">PMC8815774</ArticleId><ArticleId IdType="pubmed">35108514</ArticleId></ArticleIdList></Reference><Reference><Citation>Francomano F, Caruso A, Barbarossa A, Fazio A, La Torre C, Ceramella J, et al. &#x3b2;-Caryophyllene: a sesquiterpene with countless biological properties. Appl Sci. (2019) 9:5420.</Citation></Reference><Reference><Citation>Scandiffio R, Geddo F, Cottone E, Querio G, Antoniotti S, Gallo MP, et al. Protective effects of (E)-beta-caryophyllene (BCP) in chronic inflammation. Nutrients. (2020) 12:3273. 10.3390/nu12113273</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12113273</ArticleId><ArticleId IdType="pmc">PMC7692661</ArticleId><ArticleId IdType="pubmed">33114564</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha NK, Sharma C, Hashiesh HM, Arunachalam S, Meeran MN, Javed H, et al. beta-caryophyllene, a natural dietary CB2 receptor selective cannabinoid can be a candidate to target the trinity of infection, immunity, and inflammation in COVID-19. Front Pharmacol. (2021) 12:590201. 10.3389/fphar.2021.590201</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.590201</ArticleId><ArticleId IdType="pmc">PMC8163236</ArticleId><ArticleId IdType="pubmed">34054510</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz C, Karali K, Fodelianaki G, Gravanis A, Chavakis T, Charalampopoulos I, et al. Neurosteroids as regulators of neuroinflammation. Front Neuroendocrinol. (2019) 55:100788. 10.1016/j.yfrne.2019.100788</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yfrne.2019.100788</ArticleId><ArticleId IdType="pubmed">31513776</ArticleId></ArticleIdList></Reference><Reference><Citation>Naylor JC, Kilts JD, Shampine LJ, Parke GJ, Wagner HR, Szabo ST, et al. Effect of pregnenolone vs placebo on self-reported chronic low back pain among US military veterans: a randomized clinical trial. JAMA Netw Open. (2020) 3:e200287. 10.1001/jamanetworkopen.2020.0287</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.0287</ArticleId><ArticleId IdType="pmc">PMC7052727</ArticleId><ArticleId IdType="pubmed">32119096</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinna G. Sex and COVID-19: a protective role for reproductive steroids. Trends Endocrinol Metab. (2021) 32:3&#x2013;6. 10.1016/j.tem.2020.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2020.11.004</ArticleId><ArticleId IdType="pmc">PMC7649655</ArticleId><ArticleId IdType="pubmed">33229187</ArticleId></ArticleIdList></Reference><Reference><Citation>Straub RH, Scholmerich J, Zietz B. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases&#x2013;substitutes of adrenal and sex hormones. Z Rheumatol. (2000) 59(Suppl. 2):II/108&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">11155790</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberbeck R, Dahlweid M, Koch R, van Griensven M, Emmendorfer A, Tscherne H, et al. Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Crit Care Med. (2001) 29:380&#x2013;4. 10.1097/00003246-200102000-00029</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200102000-00029</ArticleId><ArticleId IdType="pubmed">11246320</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves VB, Basso PJ, Nardini V, Silva A, Chica JE, Cardoso CR. Dehydroepiandrosterone (DHEA) restrains intestinal inflammation by rendering leukocytes hyporesponsive and balancing colitogenic inflammatory responses. Immunobiology. (2016) 221:934&#x2013;43. 10.1016/j.imbio.2016.05.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2016.05.013</ArticleId><ArticleId IdType="pubmed">27263829</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavan R, Jain S, Shraddha, Kumar A. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. (2012) 2012:976203. 10.1155/2012/976203</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/976203</ArticleId><ArticleId IdType="pmc">PMC3529416</ArticleId><ArticleId IdType="pubmed">23304525</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathnavelu V, Alitheen NB, Sohila S, Kanagesan S, Ramesh R. Potential role of bromelain in clinical and therapeutic applications. Biomed Rep. (2016) 5:283&#x2013;8. 10.3892/br.2016.720</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/br.2016.720</ArticleId><ArticleId IdType="pmc">PMC4998156</ArticleId><ArticleId IdType="pubmed">27602208</ArticleId></ArticleIdList></Reference><Reference><Citation>Owoyele BV, Bakare AO, Ologe MO. Bromelain: a review on its potential as a therapy for the management of Covid-19. Niger J Physiol Sci. (2020) 35:10&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33084621</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagar S, Rathinavel AK, Lutz WE, Struble LR, Khurana S, Schnaubelt AT, et al. Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein. Clin Transl Med. (2021) 11:e281. 10.1002/ctm2.281</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.281</ArticleId><ArticleId IdType="pmc">PMC7811777</ArticleId><ArticleId IdType="pubmed">33635001</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiradentes RV, Pires JG, Silva NF, Ramage AG, Santuzzi CH, Futuro Neto HA. Effects of acute administration of selective serotonin reuptake inhibitors on sympathetic nerve activity. Braz J Med Biol Res. (2014) 47:554&#x2013;9. 10.1590/1414-431x20143698</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1414-431x20143698</ArticleId><ArticleId IdType="pmc">PMC4123834</ArticleId><ArticleId IdType="pubmed">25003632</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al. Autonomic dysfunction in &#x2018;long COVID&#x2019;: rationale, physiology and management strategies. Clin Med (Lond). (2021) 21:e63&#x2013;7. 10.7861/clinmed.2020-0896</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0896</ArticleId><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui MZ. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharm Sci. (2011) 73:255&#x2013;61. 10.4103/0250-474X.93507</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0250-474X.93507</ArticleId><ArticleId IdType="pmc">PMC3309643</ArticleId><ArticleId IdType="pubmed">22457547</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomaa AA, Mohamed HS, Abd-Ellatief RB, Gomaa MA. Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly. Inflammopharmacology. (2021) 29:1033&#x2013;48. 10.1007/s10787-021-00841-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-021-00841-8</ArticleId><ArticleId IdType="pmc">PMC8256410</ArticleId><ArticleId IdType="pubmed">34224069</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati K, Verma P, Rai N, Ray A. Chapter 7 &#x2013; role of nutraceuticals in respiratory and allied diseases. In: Gupta RC Lall R Srivastava A editors. Nutraceuticals (Second Edition). Cambridge, MA: Academic Press; (2021). p. 101&#x2013;15.</Citation></Reference><Reference><Citation>Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, et al. Quercetin, inflammation and immunity. Nutrients. (2016) 8:167. 10.3390/nu8030167</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu8030167</ArticleId><ArticleId IdType="pmc">PMC4808895</ArticleId><ArticleId IdType="pubmed">26999194</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal PK, Agrawal C, Blunden G. Quercetin: antiviral significance and possible COVID-19 integrative considerations. Nat Product Commun. (2020) 15:1934578X20976293. 10.1177/1934578X20976293</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1934578X20976293</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeedi-Boroujeni A, Mahmoudian-Sani MR. Anti-inflammatory potential of Quercetin in COVID-19 treatment. J Inflamm (Lond). (2021) 18:3. 10.1186/s12950-021-00268-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12950-021-00268-6</ArticleId><ArticleId IdType="pmc">PMC7840793</ArticleId><ArticleId IdType="pubmed">33509217</ArticleId></ArticleIdList></Reference><Reference><Citation>Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. The role of zinc in antiviral immunity. Adv Nutr. (2019) 10:696&#x2013;710. 10.1093/advances/nmz013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/advances/nmz013</ArticleId><ArticleId IdType="pmc">PMC6628855</ArticleId><ArticleId IdType="pubmed">31305906</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels I, Rolles B, Rink L. The potential impact of zinc supplementation on COVID-19 pathogenesis. Front Immunol. (2020) 11:1712. 10.3389/fimmu.2020.01712</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01712</ArticleId><ArticleId IdType="pmc">PMC7365891</ArticleId><ArticleId IdType="pubmed">32754164</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemian R, Shamshirian A, Heydari K, Malekan M, Alizadeh-Navaei R, Ebrahimzadeh MA, et al. The role of vitamin D in the age of COVID-19: a systematic review and meta-analysis. Int J Clin Pract. (2021) 75:e14675. 10.1111/ijcp.14675</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14675</ArticleId><ArticleId IdType="pmc">PMC8420549</ArticleId><ArticleId IdType="pubmed">34322971</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou AG, Jahaj E, Orfanos SE, Dimopoulou I, Kotanidou A. Vitamin D in infectious complications in critically ill patients with or without COVID-19. Metabol Open. (2021) 11:100106. 10.1016/j.metop.2021.100106</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2021.100106</ArticleId><ArticleId IdType="pmc">PMC8261135</ArticleId><ArticleId IdType="pubmed">34250458</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai SHC, Sharma N, Kwong AC, Dwivedi DJ, Khan M, Grin PM, et al. Body temperature and mouse scoring systems as surrogate markers of death in cecal ligation and puncture sepsis. Intensive Care Med Exp. (2018) 6:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6063809</ArticleId><ArticleId IdType="pubmed">30054760</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahuranec DB, Skolarus LE, Feng C, Freedman VA, Burke JF. Activity limitations and subjective well-being after stroke. Neurology. (2017) 89:944&#x2013;50. 10.1212/WNL.0000000000004286</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004286</ArticleId><ArticleId IdType="pmc">PMC5577967</ArticleId><ArticleId IdType="pubmed">28733341</ArticleId></ArticleIdList></Reference><Reference><Citation>Vall&#xe9;e M, Vitiello S, Bellocchio L, H&#xe9;bert-Chatelain E, Monlezun S, Martin-Garcia E, et al. Pregnenolone can protect the brain from cannabis intoxication. Science. (2014) 343:94&#x2013;8. 10.1126/science.1243985</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1243985</ArticleId><ArticleId IdType="pmc">PMC4057431</ArticleId><ArticleId IdType="pubmed">24385629</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. (1993) 365:61&#x2013;5. 10.1038/365061a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/365061a0</ArticleId><ArticleId IdType="pubmed">7689702</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosato M, Ciciarello F, Zazzara MB, Pais C, Savera G, Picca A, et al. Nutraceuticals and dietary supplements for older adults with long COVID-19. Clin Geriatr Med. (2022) 38:565&#x2013;91. 10.1016/j.cger.2022.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cger.2022.04.004</ArticleId><ArticleId IdType="pmc">PMC9212635</ArticleId><ArticleId IdType="pubmed">35868674</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>